TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT02874404 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions

DRUG: Ibrutinib
OTHER: Laboratory Biomarker Analysis
DRUG: PI3K-delta Inhibitor TGR-1202

Sponsor

University of Nebraska

Collaborators

[object Object]